Charles Schwab Investment Management Inc. Acquires 273,604 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Charles Schwab Investment Management Inc. grew its holdings in Acelyrin, Inc. (NASDAQ:SLRN) by 81.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 609,678 shares of the company’s stock after purchasing an additional 273,604 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.61% of Acelyrin worth $3,006,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in SLRN. Intech Investment Management LLC acquired a new position in Acelyrin during the 3rd quarter worth about $77,000. US Bancorp DE lifted its position in shares of Acelyrin by 77.1% during the third quarter. US Bancorp DE now owns 16,854 shares of the company’s stock worth $83,000 after purchasing an additional 7,336 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Acelyrin by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,196 shares of the company’s stock valued at $95,000 after purchasing an additional 7,560 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of Acelyrin by 129.6% in the third quarter. SG Americas Securities LLC now owns 26,755 shares of the company’s stock valued at $132,000 after purchasing an additional 15,101 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in Acelyrin by 158.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 90,022 shares of the company’s stock worth $397,000 after buying an additional 55,141 shares in the last quarter. Institutional investors own 87.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SLRN. Wells Fargo & Company dropped their target price on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday. Morgan Stanley reduced their target price on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Monday, August 19th. Finally, HC Wainwright reissued a “neutral” rating and set a $8.00 price target on shares of Acelyrin in a research note on Wednesday.

Acelyrin Trading Down 8.8 %

Shares of SLRN opened at $3.23 on Friday. The stock has a market cap of $324.07 million, a P/E ratio of -1.31 and a beta of 1.61. The stock’s 50-day moving average price is $5.17 and its two-hundred day moving average price is $4.99. Acelyrin, Inc. has a 1 year low of $3.14 and a 1 year high of $8.89.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.